Study Title
PARC: A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood
Protocol ID
RG_16-040 (PARC)
Condition/s
All Paediatric Cancer Types
Diagnosis Stage
Relapse/ refractory
Location
NSW, VIC, WA, SA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University of Birmingham
University of Birmingham
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 year to 25 years
International registry ID's
NCT03455140
| Study Title | PARC: A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood |
|---|---|
| Protocol ID | RG_16-040 (PARC) |
| Disease (Sub Disease) | All Paediatric Cancer Types |
| Diagnosis Stage | Relapse/ refractory |
| Location | NSW / VIC / WA / SA |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ University of Birmingham |
| Links | https://clinicaltrials.gov/ct2/show/NCT03455140 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 29/11/2019 |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 1 year to 25 years |
| International registry ID's | NCT03455140 |